跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
KAVIGALE 300 MG SOLUCION INYECTABLE Y PARA PERFUSION - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
KAVIGALE 300 MG SOLUCION INYECTABLE Y PARA PERFUSION
Approved
STANDARD
KAVIGALE 300 MG SOLUCION INYECTABLE Y PARA PERFUSION
Astrazeneca Ab
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Jan 29, 2025
Approval ID
81cb4f4d30444919
Company
Astrazeneca Ab
Type
Standard
Approval Details
Approval Id
81cb4f4d30444919
Drug Cima Aemps Name
KAVIGALE 300 MG SOLUCION INYECTABLE Y PARA PERFUSION
Register Number
1241900001
Holder Company Name
Astrazeneca Ab
Marketing Company Name
Astrazeneca Farmaceutica Spain S.A.
Holder Company Detail Path
/organization/astrazeneca-ab
Authorization Date
2025-01-29
Dosage Form
SOLUCIÓN INYECTABLE Y PARA PERFUSIÓN
Dose
300 mg
Route Of Administration
VÍA INTRAMUSCULAR
Prescription Type
Uso Hospitalario
Commercialized
No
Company Name
Astrazeneca Ab
Company Detail Path
/organization/astrazeneca-ab
Company Information
Pharmaceutical Company Name
ASTRAZENECA AB
Country Name
Spain
City Name
madrid,madrid,country_es
Address
CALLE RAIMUNDO FERNANDEZ VILLAVERDE 63
Website
http://www.astrazeneca.se
Active Ingredients
SIPAVIBART
300 mg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Jan 29, 2025
Approval ID
81cb4f4d30444919
Type
Standard
Back to CIMA-AEMPS Approvals
